The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Belimumab combined with SOC was successful for inducing remission among patients with SLE, including those with LN.

Curious what ChatGPT could offer the rare disease community, columnist Candace Semien used the AI tool to prepare for a ...

导读2024年美国风湿病学会(ACR)年会汇聚了众多风湿病领域的前沿研究成果，系统性红斑狼疮(SLE)相关研究是其中的重要部分。这些研究涵盖新疗法、现有疗法优化及疾病管理策略改进等方面，为SLE患者的治疗和管理带来新希望，以下为部分治疗相关重点研究的 ...

Lupus Therapeutics introduces the IDEAL Initiative to fund clinical studies exploring the impact of diet and the microbiome ...

Long-term treatment with anifrolumab may delay the onset of irreversible organ damage and reduce the damage accrual rate in patients with moderate to severe systemic lupus erythematosus (SLE), results ...

Research news last week included US biotech Fate releasing early data for its FT819 in the treatment of systemic lupus ...

Systemic Lupus Erythematosus (SLE), commonly known as lupus ... For severe cases or when organ systems are involved, treatment may include: Immunosuppressive drugs: Medications such as azathioprine, ...

This report report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and ...

Systemic lupus erythematosus (SLE) is an autoimmune disease marked by premature atherosclerosis ... Despite being a widespread problem, there is a limited availability of effective treatment options.